[Management of chemotherapy side effects and their long-term sequelae].
Zraik IM, Heß-Busch Y.
Urologe A. 2021 Jul;60(7):862-871. doi: 10.1007/s00120-021-01569-7. Epub 2021 Jun 29.
Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.
Lyman GH, Abella E, Pettengell R.
Crit Rev Oncol Hematol. 2014 Jun;90(3):190-9. doi: 10.1016/j.critrevonc.2013.12.006. Epub 2013 Dec 12.
Enteral tube administration of oral chemotherapy drugs.
Spencer SH, Menard SM, Labedz MZ, Krueger CD, Sarna KV.
J Oncol Pharm Pract. 2020 Apr;26(3):703-717. doi: 10.1177/1078155219893449. Epub 2020 Jan 19.
Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring.
Knezevic CE, Clarke W.
Ther Drug Monit. 2020 Feb;42(1):6-19. doi: 10.1097/FTD.0000000000000701.
[Chemotherapy].
Fujita S, Kotake K.
Nihon Rinsho. 2014 Jan;72(1):102-7.
Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy.
Ippolito MR, Martis V, Martin S, Tijhuis AE, Hong C, Wardenaar R, Dumont M, Zerbib J, Spierings DCJ, Fachinetti D, Ben-David U, Foijer F, Santaguida S.
Dev Cell. 2021 Sep 13;56(17):2440-2454.e6. doi: 10.1016/j.devcel.2021.07.006. Epub 2021 Aug 4.
Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers.
Davern M, Lysaght J.
Cancer Lett. 2020 Dec 28;495:89-99. doi: 10.1016/j.canlet.2020.09.014. Epub 2020 Sep 17.
Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S, Kondo S.
Expert Opin Pharmacother. 2018 Jun;19(9):993-1001. doi: 10.1080/14656566.2018.1479398. Epub 2018 Jun 18.
Danger signals: Chemotherapy enhancers?
Rivera Vargas T, Apetoh L.
Immunol Rev. 2017 Nov;280(1):175-193. doi: 10.1111/imr.12581.
Targeting FAK in anticancer combination therapies.
Dawson JC, Serrels A, Stupack DG, Schlaepfer DD, Frame MC.
Nat Rev Cancer. 2021 May;21(5):313-324. doi: 10.1038/s41568-021-00340-6. Epub 2021 Mar 17.
